Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.

Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.

Sunmo succeeds in a setting very similar to Starglo's.

The group is aiming for accelerated approval with the upcoming Alpacca trial.

When your investment case breaks down, why not just do the decent thing?

The registrational part 2 of bezuclastinib's Summit trial reads out in July.